Drugs /

sar440234

Back to Drugs List

Overview

NCI Definition [1]:
A bispecific T-cell engager (BiTE) antibody comprised of a humanized Fc-silenced immunoglobulin G1 (IgG1) backbone and two single-chain variable fragments (scFvs): one directed against the CD3 antigen expressed on T-lymphocytes and another directed against the alpha-chain of the interleukin-3 receptor (IL-3RA; CD123), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, anti-CD123/CD3 BiTE antibody SAR440234 binds to both CD3 expressed on T-cells and CD123 expressed on tumor cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CD123-expressing tumor cells, leading to enhanced CTL-mediated elimination of CD123-expressing tumor cells. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.

Clinical Trials

View Clinical Trials for sar440234

Sar440234 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating sar440234, 1 is phase 1/phase 2 (0 open).

Complex karyotype, Loss of Y, and Monosomy 7 are the most frequent biomarker inclusion criteria for sar440234 clinical trials.

Acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and myelodysplastic syndromes are the most common diseases being investigated in sar440234 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Sar440234
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sar440234 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
sar-440234, sar 440234, cd123xcd3 bispecific t-cell engager sar440234, bispecific t-cell engager antibody sar440234, anti-cd123/cd3 bite antibody sar440234
Drug Target(s) [2]:
CD247, CD3D, CD3E, CD3G, IL3RA
NCIT ID [1]:
C160348

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.